Next Article in Journal
Assessment of Exposure to Mycotoxins in Spanish Children through the Analysis of Their Levels in Plasma Samples
Previous Article in Journal
The Effectiveness of Dietary Byproduct Antioxidants on Induced CYP Genes Expression and Histological Alteration in Piglets Liver and Kidney Fed with Aflatoxin B1 and Ochratoxin A
Open AccessReview

Real Impact of Novel Immunotherapy Drugs in Cancer. The Experience of 10 Last Years

1
Department of Medical Oncology University General Hospital of Heraklion, University of Crete, 71003 Heraklion, Greece
2
Faculty of Medicine, University of Crete, 71003 Heraklion, Greece
3
1st Oncology Department, “Saint Savas” Anticancer—Oncology Hospital, 11522 Athens, Greece
*
Author to whom correspondence should be addressed.
Received: 10 January 2021 / Revised: 4 February 2021 / Accepted: 9 February 2021 / Published: 15 February 2021
Intense research on immunotherapy has been conducted during recent years. As advances in the field have started changing the landscape of cancer therapy, it is necessary to assess the impact of immunotherapeutic modalities in the treatment of various cancers. Ten years ago, in 2011, ipilimumab was the first of the newest immunotherapeutic drugs against cancer to be approved by the FDA. Then several drugs followed and formed a therapeutic arsenal to fight cancer. Initial studies were performed on metastatic patients, but there are currently several studies in patients with potentially curable cancers. All these developments have created a new environment for oncology which we will present in this article. This review examines the current evidence related to the impact of immunotherapy on various cancers and discusses its potential clinical and research implications, including its effectiveness in comparison to other treatment modalities (chemotherapy, radiotherapy), its toxicity and prospective research opportunities. While constant updates and further research is critical to understand the impact of immunotherapy in cancer therapy, not only does it seem to be important to assess the current state of knowledge highlighting the success but also to determine the challenging aspects of cancer immunotherapy. View Full-Text
Keywords: immunotherapy; checkpoint inhibitors; cancer treatment; toxicity; PD-1; PD-L1; CTLA-4 immunotherapy; checkpoint inhibitors; cancer treatment; toxicity; PD-1; PD-L1; CTLA-4
Show Figures

Figure 1

MDPI and ACS Style

Koulouris, A.; Tsagkaris, C.; Nikolaou, M. Real Impact of Novel Immunotherapy Drugs in Cancer. The Experience of 10 Last Years. Toxins 2021, 13, 149. https://0-doi-org.brum.beds.ac.uk/10.3390/toxins13020149

AMA Style

Koulouris A, Tsagkaris C, Nikolaou M. Real Impact of Novel Immunotherapy Drugs in Cancer. The Experience of 10 Last Years. Toxins. 2021; 13(2):149. https://0-doi-org.brum.beds.ac.uk/10.3390/toxins13020149

Chicago/Turabian Style

Koulouris, Andreas; Tsagkaris, Christos; Nikolaou, Michail. 2021. "Real Impact of Novel Immunotherapy Drugs in Cancer. The Experience of 10 Last Years" Toxins 13, no. 2: 149. https://0-doi-org.brum.beds.ac.uk/10.3390/toxins13020149

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop